Cat. No.: HY-18309

MET kinase-IN-4

Customer Review

Based on 1 Customer Validation

MET kinase-IN-4 is an orally active Met kinase inhibitor. MET kinase-IN-4 has potent Met kinase inhibitory activity with an IC₅₀ value of 1.9 nM. MET kinase-IN-4 can be used for the research of cancer.

For research use only. We do not sell to patients.

Purity: 99.00%
CAS No.: 888719-03-7
Formula: C₂₅H₁₆F₂N₄O₃
Molecular Weight:458.42

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

MET kinase-IN-4 Chemical Structure

CAS No.: 888719-03-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 1.9 nM (Met); 4 nM (Flt-3); 27 nM (VEGFR-2)^[1]

All VEGFR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
GTL 16 cell line	IC₅₀	60 nM Compound: 2	Antiproliferative activity against human GTL16 cells after 72 hrs by MTS assay Antiproliferative activity against human GTL16 cells after 72 hrs by MTS assay	[PMID: 18690676]
GTL 16 cell line	IC₅₀	60 nM Compound: 1	Antiproliferative activity against Met-dependent human GTL16 cells after 72 hrs by MTS assay Antiproliferative activity against Met-dependent human GTL16 cells after 72 hrs by MTS assay	[PMID: 19260711]
NCI-N87	IC₅₀	>5000 nM Compound: 2	Antiproliferative activity against human N87 cells after 72 hrs by MTS assay Antiproliferative activity against human N87 cells after 72 hrs by MTS assay	[PMID: 18690676]

In Vitro

MET kinase-IN-4 (Compound 2) has potent Met kinase inhibitory activity with an IC₅₀ value of 1.9 nM^[1].
MET kinase-IN-4 inhibits Flt-3 and VEGFR-2 kinases with IC₅₀ values of 4 and 27 nM, respectively^[1].
MET kinase-IN-4 (3 μM) shows good metabolic stability in both human and mouse liver microsomes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

MET kinase-IN-4 (Compound 2) (i.v., p.o.; 5, 10 mg/kg) possesses a favorable pharmacokinetic profile in mice^[1].
MET kinase-IN-4 (p.o.; 6.25, 12.5, 25 and 50 mg/kg; once a day) demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Mice^[1]
Dosage:

5, 10 mg/kg
Administration:

IV, PO
Result:

Showed extensive extravascular distribution and a favorable half-life.

Animal Model:

Nude mice^[1]
Dosage:

6.25, 12.5, 25 and 50 mg/kg
Administration:

PO, once a day
Result:

Showed antitumor activity in dose-dependet.

Chemical Information

CAS No. 888719-03-7
Appearance Solid
Molecular Weight 458.42
Formula C₂₅H₁₆F₂N₄O₃
Color Off-white to light yellow
SMILES

O=C(C1=CC=CN(C2=CC=C(F)C=C2)C1=O)NC3=CC=C(OC4=C5C(NC=C5)=NC=C4)C(F)=C3
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (218.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1814 mL

10.9070 mL

21.8141 mL

5 mM

0.4363 mL

2.1814 mL

4.3628 mL

10 mM

0.2181 mL

1.0907 mL

2.1814 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.45 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kyoung Soon Kim, et al. Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem. 2008 Sep 11;51(17):5330-41. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1814 mL	10.9070 mL	21.8141 mL	54.5351 mL
	5 mM	0.4363 mL	2.1814 mL	4.3628 mL	10.9070 mL
	10 mM	0.2181 mL	1.0907 mL	2.1814 mL	5.4535 mL
	15 mM	0.1454 mL	0.7271 mL	1.4543 mL	3.6357 mL
	20 mM	0.1091 mL	0.5454 mL	1.0907 mL	2.7268 mL
	25 mM	0.0873 mL	0.4363 mL	0.8726 mL	2.1814 mL
	30 mM	0.0727 mL	0.3636 mL	0.7271 mL	1.8178 mL
	40 mM	0.0545 mL	0.2727 mL	0.5454 mL	1.3634 mL
	50 mM	0.0436 mL	0.2181 mL	0.4363 mL	1.0907 mL
	60 mM	0.0364 mL	0.1818 mL	0.3636 mL	0.9089 mL
	80 mM	0.0273 mL	0.1363 mL	0.2727 mL	0.6817 mL
	100 mM	0.0218 mL	0.1091 mL	0.2181 mL	0.5454 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MET kinase-IN-4

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

All VEGFR Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MET kinase-IN-4

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

All VEGFR Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MET kinase-IN-4 Related Classifications

Cat. No.: HY-18309